Navigation for Press Releases & Statements

New surgical robot now treating prostate cancer patients


Men diagnosed with early prostate cancer in Gloucestershire, Herefordshire and Worcestershire are now benefitting from treatment using a new high-tech surgical robot at Cheltenham General Hospital (CGH).

To mark this significant move forward in the treatment of prostate cancer in our county, an event is taking place at CGH on 20th June at 2.30pm.

The purchase of the robot was made possible by a £1.2m investment by our Trust, with significant input from local charity Robocap to the tune of £350,000. The contribution of charity partners is always highly valued by our Trust and we are extremely grateful for the huge amount of effort, fundraising and support of the Robocap Charity, its Patron Dame Janet Trotter, Trustees and the people of Gloucestershire, Herefordshire and South Worcestershire who helped to raise this significant proportion of the funds.


Money raised by Robocap will also go towards providing several clinical accessories which are required for the procedure. Additional funding of £4,500 was provided by the generosity of the Friends of GRH charity.

Since March this year, consultants and theatre practitioners have undergone extensive training on the use of the state-of-the-art robot, which allows surgeons to use 3D vision and high-precision instruments to remove the prostate in affected men with cancer.

As well as improving outcomes for men with prostate cancer, the new treatment should reduce the side effects of surgery and the length of stay for these patients by more than half. The robot is made up of a console operated by the surgeon and a patient-side system with four robotic arms that execute the surgeon's commands. The Da Vinci surgical system has revolutionised surgical treatment for prostate cancer by making it possible for surgeons to perform minimally-invasive surgery with greater precision and control than ever before.

Biral Patel, Consultant Urological Surgeon said: "Our aim is to improve the diagnosis and management of early prostate cancer in the region by using the best available techniques and equipment. We are determined to keep up with developing technologies in order to make sure we continue to deliver the very best for our patients.”